Abeona TherapeuticsABEO
Market Cap: 209M
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Employees: 84
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
1,131% more call options, than puts
Call options by funds: $5.18M | Put options by funds: $421K
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
28% more capital invested
Capital invested by funds: $82.1M [Q4 2023] → $105M (+$22.6M) [Q1 2024]
17% more funds holding
Funds holding: 48 [Q4 2023] → 56 (+8) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]
13.36% less ownership
Funds ownership: 66.17% [Q4 2023] → 52.81% (-13.36%) [Q1 2024]
Research analyst outlook
5 Wall Street Analysts provided 1 year price forecasts over the past 6 months
5 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju | 194%upside $15 | Buy Reiterated | 12 Jul 2024 |
HC Wainwright & Co. Raghuram Selvaraju | 194%upside $15 | Buy Initiated | 3 Jul 2024 |
Stifel Dae Gon Ha | 312%upside $21 | Buy Initiated | 30 May 2024 |
Cantor Fitzgerald Kristen Kluska | 312%upside $21 | Overweight Maintained | 16 May 2024 |
Cantor Fitzgerald Kristen Kluska | 606%upside $36 | Overweight Reiterated | 23 Apr 2024 |
Financial journalist opinion
Based on 3 articles about ABEO published over the past 30 days